Inicio › Melanoma › Massachusetts › Boston
Ensayos clínicos de Melanoma en Boston, MA
25 estudios para Melanoma buscan participantes en centros de Boston y alrededores (a unos 30 millas). Abra un estudio para ver quién puede participar y cómo contactar con el equipo.
Texto oficial del estudio (inglés)
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
ReclutandoFase 1/2
- Call for Information (Investigational Site 0026), Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
ReclutandoFase 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
ReclutandoFase 2
- Local Institution - 0124, Boston
Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
ReclutandoFase 2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
ReclutandoFase 1/2
- Tufts Medical Center, Boston
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
ReclutandoFase 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Institute, Boston
Cryoablation+Ipilimumab+Nivolumab in Melanoma
ReclutandoFase 2
- Massachusetts General Hospital Cancer Center, Boston
Project: Every Child for Younger Patients With Cancer
ReclutandoEstudio observacional
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
ReclutandoFase 1/2
- Dana-Farber Cancer Institute, Boston
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital Cancer Center, Boston
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
ReclutandoFase 1/2
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Neoadjuvant Darovasertib in Primary Uveal Melanoma
ReclutandoFase 3
- Massachusetts General Hospital, Boston
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
ReclutandoFase 2/3
- Dana Farber, Boston
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
ReclutandoFase 2/3
- Massachusetts General Hospital, Boston
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
ReclutandoFase 3
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
ACTengine® IMA203 Combined With mRNA-4203
ReclutandoFase 1
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
ReclutandoFase 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
ReclutandoFase 2
- Dana Farber Cancer Institute, Boston
Más información sobre Melanoma en MedlinePlus
Ensayos de Melanoma en otras ciudades
- Houston, TX61 estudios
- New York City, NY41 estudios
- Nashville, TN34 estudios
- Los Angeles, CA34 estudios
- Pittsburgh, PA31 estudios
- St. Louis, MO23 estudios
- Durham, NC22 estudios
- Philadelphia, PA22 estudios
- Tampa, FL21 estudios
- Columbus, OH21 estudios
- Dallas, TX21 estudios
- San Francisco, CA21 estudios
Otros estudios en Boston
- Cáncer de seno110 estudios
- Cáncer (todos los tipos)90 estudios
- Cáncer de pulmón de células no pequeñas87 estudios
- Cáncer de pulmón63 estudios
- Cáncer del colon y del recto62 estudios
- Cáncer de ovario62 estudios
- Cáncer metastásico61 estudios
- Cáncer de próstata56 estudios
- Cáncer de endometrio51 estudios
- Depresión50 estudios
- Fallo cardíaco46 estudios
- Mieloma múltiple45 estudios
De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.